NUWE vs. GCTK, NAOV, BJDX, TTOO, IVF, LGMK, BBLG, AVGR, DYNT, and NAYA
Should you be buying Nuwellis stock or one of its competitors? The main competitors of Nuwellis include GlucoTrack (GCTK), Nanovibronix (NAOV), Bluejay Diagnostics (BJDX), T2 Biosystems (TTOO), INVO Fertility (IVF), LogicMark (LGMK), Bone Biologics (BBLG), Avinger (AVGR), Dynatronics (DYNT), and NAYA Biosciences (NAYA). These companies are all part of the "medical equipment" industry.
Nuwellis vs. Its Competitors
GlucoTrack (NASDAQ:GCTK) and Nuwellis (NASDAQ:NUWE) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, profitability, analyst recommendations, valuation, earnings and risk.
Nuwellis has higher revenue and earnings than GlucoTrack. GlucoTrack is trading at a lower price-to-earnings ratio than Nuwellis, indicating that it is currently the more affordable of the two stocks.
10.9% of GlucoTrack shares are owned by institutional investors. Comparatively, 3.1% of Nuwellis shares are owned by institutional investors. 12.9% of GlucoTrack shares are owned by company insiders. Comparatively, 1.6% of Nuwellis shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
GlucoTrack has a beta of -0.24, suggesting that its stock price is 124% less volatile than the S&P 500. Comparatively, Nuwellis has a beta of 0.28, suggesting that its stock price is 72% less volatile than the S&P 500.
In the previous week, Nuwellis had 3 more articles in the media than GlucoTrack. MarketBeat recorded 5 mentions for Nuwellis and 2 mentions for GlucoTrack. GlucoTrack's average media sentiment score of 1.35 beat Nuwellis' score of 0.24 indicating that GlucoTrack is being referred to more favorably in the media.
Nuwellis has a consensus price target of $714.00, suggesting a potential upside of 5,791.09%. Given Nuwellis' stronger consensus rating and higher probable upside, analysts clearly believe Nuwellis is more favorable than GlucoTrack.
GlucoTrack has a net margin of 0.00% compared to Nuwellis' net margin of -112.09%. GlucoTrack's return on equity of 0.00% beat Nuwellis' return on equity.
Summary
Nuwellis beats GlucoTrack on 9 of the 15 factors compared between the two stocks.
Get Nuwellis News Delivered to You Automatically
Sign up to receive the latest news and ratings for NUWE and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding NUWE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Nuwellis Competitors List
Related Companies and Tools
This page (NASDAQ:NUWE) was last updated on 7/25/2025 by MarketBeat.com Staff
